Mark Jeffrey DeLong, Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 367 shares at $64.14 ($24K) on 2024-01-29, disclosed to the SEC on 2024-01-31.
Open-market sale of $24k APLS by Chief Business & Strat Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| APLS | SELL | 2026-01-21 | $26K | — | Filing → |
| APLS | SELL | 2026-01-15 | $39K | — | Filing → |
| APLS | SELL | 2025-02-12 | $10K | — | Filing → |